中牧股份(600195.SH):榮獲國家科學技術進步獎二等獎
格隆匯11月5日丨中牧股份(600195.SH)公佈,2021年11月3日,2020年度國家科學技術獎勵大會在人民大會堂隆重召開。由公司等單位合作申報的“奶牛高發病防治系列新獸藥創制與應用”研究成果,獲得國家科學技術進步獎二等獎。
“奶牛高發病防治系列新獸藥創制與應用”研究成果,摸清了奶牛高發病病原種屬及分佈規律,創新了藥物製備“共性和差異化”的關鍵技術,創制了奶牛用安全高效系列新獸藥31種,填補了國內獸藥領域多項空白,實現了奶牛養殖產業鏈“全覆蓋”,為解決困擾奶牛養殖業多年來的疾病難題和多項獸藥產品研製的行業關鍵共性問題作出重要貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.